Allogeneic donor and iPSC master cell banks
Making cell therapies from a healthy donor or stem-cell line in advance, so patients get an off-the-shelf product instead of waiting weeks.
Off-the-shelf products use healthy-donor T or NK cells (Allogene, Caribou, Cellectis, Takeda/MD Anderson cord-blood NK) or induced pluripotent stem cell master banks (Fate Therapeutics, Century, Shoreline, Cellular Biomedicine) edited to avoid graft-versus-host disease and host rejection. Banking, donor eligibility, and comparability across thousands of doses from one bank are the manufacturing questions; durability of response is the clinical one.
How it works
A characterised master cell bank (donor or iPSC) is expanded, gene-edited to remove TCR and HLA class I, differentiated if needed, and cryopreserved in hundreds of doses per batch.
- Immediate availability
- Lower cost per dose at scale
- Consistent product
- Rejection limits persistence
- Editing complexity
- Donor-to-donor variability for primary-cell products
Latest papers
topQuery for this technology: (TITLE:"Allogeneic donor and iPSC master cell banks" OR ABSTRACT:"Allogeneic donor and iPSC master cell banks") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about Allogeneic donor and iPSC master cell banks, not a curated reading list.
Pages like this
not linked directly; found by shared links- TechnologyCell-therapy orchestration and chain-of-identity software
Shares Cryopreservation and cell-therapy cold chain, CAR-T cell therapy and the tag supporting.
- CompanyBioLife Solutions
Shares Cryopreservation and cell-therapy cold chain and the tag supporting.
- CompanyCryoport
Shares Cryopreservation and cell-therapy cold chain and the tag supporting.
- TechnologyApheresis and starting-material collection
Shares Cryopreservation and cell-therapy cold chain, CAR-T cell therapy and the tag supporting.
- TechnologyPoint-of-care and decentralised cell manufacturing
Shares UCART19: the first gene-edited, donor-derived CAR-T cells in children and adults with relapsed B-cell ALL, CAR-T cell therapy and the tag supporting.
- TechnologyCell-therapy release and potency testing
Shares CAR-T cell therapy and the tag supporting.
- TechnologyClosed automated cell-therapy manufacturing
Shares CAR-T cell therapy and the tag supporting.
- TechnologyViral vector manufacturing (lentiviral, retroviral, AAV)
Shares CAR-T cell therapy and the tag supporting.